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Abstract
Mosquitoes are one of the most dangerous insects in the world for humanity. Over one
million people worldwide die from mosquito-borne diseases every year. Mosquito vec‐
tored diseases include protozoan diseases, i.e., malaria, filarial diseases such as dog heart‐
worm, and viral diseases such as dengue, encephalitis, and yellow fever. In addition,
mosquitoes transmit several diseases and parasites that dogs and horses are very suscep‐
tible too. These include dog heartworm, West Nile virus (WNV), and eastern equine en‐
cephalitis (EEE). Since its discovery, chemical insecticides have represented the most
widely method used to control mosquito-borne vectors. However, the effects of chemical
insecticides on mosquito vector populations are usually transitory because vectors can
rapidly develop resistance against them. Each insecticide triggers the selection of one or
more mechanisms of resistance. These mechanisms include changes in the target site of
action and metabolic detoxification among others.
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1. Introduction
Mosquito-borne vectors are responsible for the transmission of various causative agents of
infectious diseases that can be lethal for humans. During the last decades, several diseases have
increased incidence and expanded into new geographical areas. Among the factors that can
favor the spread of disease are the increase of population density, the increase of international
travel, and the increase of the import and export of goods at international level [1]. The number
of recent notifications of mosquito-borne diseases in the world is a matter of concern, and
currently there are no effective vaccines available against most of these diseases. In many parts
of the world, mosquito presence is a problem because each season presents different species
that are vectors of diseases with medical and animal importance because they feed from man
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and other organisms. Therefore, the only way to avoid epidemics of mosquito-borne diseases
is through the control of insect vectors and through knowledge of its biology, behavior, and
environmental factors that facilitate its transmission [2].
Mosquitoes’ vector characteristics vary depending on the particular conditions of their habitat
of origin. During its life cycle, mosquito goes through four stages, which are egg, larva, pup,
and adult, of which the first three stages need stagnant water to develop. Generally, adult
mosquitoes are small insects, fragile, with slender bodies, a pair of narrow wings and three
pairs of long slender legs. They vary in length from 3.16 to 1.2 inch (5 to 13 mm). They are
equipped with an elongated proboscis with mouthparts adapted for piercing skin, which the
female uses for snacks and to feed on blood.
Over the last decades, the struggle of pests has been based on the large-scale use of chemical
pesticides, as well as the elimination of all containers, artificial or natural, which can be given
favorable conditions for the development of the prolific mosquito breeding sites [3]. However,
the negative effects of chemicals on nontarget organism populations and the resistance
development to these chemicals in mosquitoes, along with the resent resurgence of different
diseases transmitted by mosquitoes, have led to search other alternative methods, more simple
and sustainable for mosquito control.
2. Mosquito-borne diseases
With the recent expansion of Aedes albopictus, there are epidemiological reports for several
mosquito-borne diseases occurred in various parts of Europe [4]. These evidences show that
the problem does not constitute an exclusive problem of tropical, subtropical, and/or devel‐
oping countries. In North America, several mosquito vectors species of the Culex, Anopheles,
and Aedes genera that transmit several diseases to humans are present [5]. Meanwhile, in
Central and South America, the main disease in humans transmitted by mosquito vectors of
the Anopheles, Aedes, Culex, and Ocherotatus genera are malaria, dengue, yellow fever, filariasis,
St. Louis encephalitis, and western equine encephalitis [6].
Mosquito-borne diseases occur when the specific biological agent that causes the disease is
transmitted to human hosts through a nonhuman carrier called vector. Therefore, the chain of
transmission involves three factors: one host, usually a human, an invertebrate vector respon‐
sible for spreading the disease, and the biological agent that may be a virus, bacterium, or
parasite. Vectors may act biologically or mechanically, where the mechanical vectors only
transport the pathogenic agent; however, in biological vectors, agent develops and multiplies
before becoming infective to the vertebrate host [7]. In that context, mosquito-borne diseases
of public health importance are complex, and its occurrence will depend on the interaction of
various factors such as biological, ecological, social, and economic factors [8].
2.1. Malaria
Malaria or paludism is caused by parasites of genus Plasmodium, which is transmitted to
humans by the bite of female Anopheles mosquitoes. Plasmodium falciporum is responsible for
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most severe cases, usually causing coma or anemia in patients, which flows into death.
Meanwhile, Plasmodium vivax causes recurring fevers and lesions in the brain and liver, but it
rarely causes death [9]. Within the measures applied to control, Anopheles vectors, for a long
time, was based on the application of DDT (1,1,1-trichloro-2,2-bis [ρ-chorophenyl] ethane), but
currently it is beginning to use pyrethroids in outbreaks and transmission foci [10].
While the disease appeared to be under control in the 1950s, the infection again reappeared in
many countries due to the resistance generated by vectors to insecticides of plasmodia and
chloroquine. This disease is responsible for the deaths of between 700,000 and 2.7 million
people [11]. Moreover, malaria causes between 400 and 900 million cases of acute fever per
year in children fewer than five years in these areas. Therefore, malaria is the disease with the
highest prevalence in areas with limited economic resources, causing the largest number of
cases in the warm and rainy seasons. The solution to eradicate this disease would be the
application of vaccine [12].
2.2. Yellow fever
This disease is caused by the yellow fever virus, an arbovirus, belonging to the Flavivirus genus
is present in tropical areas of Africa and South America. Aedes aegypti mosquito is the most
important vector in the transmission of the yellow fever disease in America [13]. Yellow fever
virus infects both humans and monkeys, being monkeys the main reservoir of infection and
transmission from monkey to monkey in woodlands and jungle. Haemagogus jantinomys and
Sabethes choropterus mosquitoes are the vectors responsible for the transovarially virus
transmission among the primate species [14]. On the other hand, the infection is transmitted
to humans through A. aegypti mosquito bites. Yellow fever virus causes 200,000 clinical cases
of disease and 30,000 deaths each year, of which 90% of the cases correspond to the African
continent [15]. Unfortunately, the most of the cases and deaths are not recognized because it
occurs in rural areas where surveillance and reporting are inadequate. Yellow fever distribu‐
tion in America ranged from Philadelphia, in the United States, until the line connecting Bahía
Blanca and Mendoza in Argentina. On the other hand, in Africa, it is located in the sub-Saharan
Africa [16]. This disease can be fatal and acute or mild and inapparent. Because there is no
specific antiviral treatment against it, the best strategy to prevent its spread is the prevention
of infection [17]. In this context, vaccination is the best preventive measure against yellow
fever.
2.3. Dengue
Dengue is a viral disease caused by infection of four viruses, known as dengue 1, 2, 3, and 4,
which is endemic in more than 100 countries in Africa, America, the Eastern Mediterranean,
Southeast Asia, and the Western Pacific, the latter two being the most severely affected. These
viruses belong to the genus Flavivirus, Flaviciridae family. The most important mosquito vector
is A. aegypti and to a lesser degree A. albopictus. Once an infected mosquito bites a human, the
virus goes through an incubation period of between 3 and 14 days before disease symptoms
appear. Furthermore, passive dispersion through means of transport is one of the most
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important factors that favor the spread of these mosquitoes and dengue virus from one region
to another.
This disease is of major interest to public health because of its great impact on morbidity and
mortality in the world since it is the viral disease transmitted by mosquito vectors most
common and important worldwide [18]. The World Health Organization estimated that there
may be 50 to 100 million dengue infections, a half-million hospitalizations, and 22,000 deaths
worldwide every year [19]. Moreover, because of the absence of a vaccine to protect the
population at risk, vector control is the most important method for the prevention and
interruption of the transmission of the disease. The use of chemical insecticides is a key
component in the control of larvae and adult mosquito vector populations. However, derived
from overuse for over five decades of these insecticides to interrupt the transmission of the
virus, it has generated resistance to different molecules of insecticides by part of mosquito
vectors [19].
2.4. Venezuelan equine encephalitis
This disease is caused by the Venezuelan equine encephalitis virus (VEE) or encephalomyelitis
in horses, donkeys, zebras, and humans. VEE virus cause acute infections in vertebrates
characterized by the presence of high viremia and disease development with varying degrees
of severity. Once the equines get the disease, they may die suddenly or present progressive
disorders of the central nervous system. Furthermore, in humans, it causes mild to severe
influenza-like symptoms, with fever and headache. Around 4–14% of cases develop neuro‐
logical complications and near 1% of reported cases die [20].
The VEE complex contains a number of virus, belonging to the Alphavirus genus of the
Togaviridae family, which have been classified into six viral subtypes, ranging from I to VI.
VEE virus are present in all continents and most often are transmitted by the bite of infected
Culex (C. vomerifer, C. pedroi, C. adamesi) and Aedes (A. taeniorhynchus) mosquito vectors and
can also be transmitted through aerosols [21]. Although virtually any mosquito can be found
infected with VEE virus during epizootics, it is thought that A. taeniorhynchus is the main vector
responsible for transmitting VEE virus during outbreaks, whereas Culex mosquitoes species
transmitted enzootic virus strains of VEE [22]. Subcutaneous injection, nasal instillation, and
contact with broken skin or bedding contaminated animals are other ways to spread the virus,
especially in a lab environment [23].
Epizootic and enzootic strains of VEE virus spread from northern Argentina to Florida and
parts of the Rocky Mountains, being more frequent in northern South America. Since 1930,
there have been 21 outbreaks of VEE throughout the American continent, being considered an
emerging disease naturally due to mutations of the enzootic and endemic virus strains that
circulate as a vector-borne disease among mammals host populations, especially in habitats
such as forests and wetlands [24]. Some of the strategies used to reduce outbreaks of VEE in
horses are through the implementation of the TC-83 vaccine and by protecting against
mosquitoes by wearing protective clothing and/or insecticides. Although, the TC-83 vaccine
is used in laboratories, there is still no licensed vaccine available to humans for the prevention
of infection by the epizootic strains of VEE virus [25].
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2.5. Japanese encephalitis
Japanese encephalitis (JE) is a viral disease transmitted to humans by mosquitoes of the Aedes
and Culex genera, where main vectors are C. tritaeniorhynchus, C. annulus, C. annulirostris, C.
vishnui, C. fuscocephala, and C. gelidus [26]. This disease affects horses, donkeys, pigs, and
humans. Due to low qualifications and shorter duration of the viremia, humans or horses
transmit the virus to other biting mosquitoes and are considered as terminal hosts [27]. The
reservoirs of JE virus are pigs and wild birds. The incubation period is around 4–14 days. In
pigs, JE causes reproductive losses (stillbirths and abortions), in horses, it causes encephalitis,
and in humans, the disease can range from very serious to no symptoms. Neurologic sequelae
occur in up to 80% of human cases and about 15,000 deaths annually [28].
JE is distributed across several areas of temperate and tropical Asia, with a higher incidence
in rural areas of Southeast Asia, the Indian subcontinent and parts of Northern Asia. It also
occurs, but less frequently in Japan, Taiwan, Singapore, Hong Kong, eastern Russia, and
Australia [29]. Although the virus affects all age-groups, regions where there have been
widespread childhood vaccination campaigns against the disease, the age distribution has
changed, increasing the proportion of cases in older children and adults [27]. Therefore, the
best alternative for control of JE it is the application of the vaccine, which is associated with
the generation of neutralizing antibodies.
2.6. Lymphatic filariasis
Lymphatic filariasis, also know elephantiasis, is a parasitic disease caused by nematodes of
the Filarioidea family, which is transmitted to humans by mosquitoes of the genus Anopheles,
Culex, Aedes, and Mansonia, which inject various nematode larvae while feed on blood [30].
The disease is present in sub-Saharan Africa and Southeast Asia. It is a chronic parasitic disease
in which adult worms lodge in the lymphatic vessels where they release microfilariae from the
bloodstream. Filariasis can produce a wide variety of clinical manifestations whose symptoms
include fever, lymphadenitis, and retrograde lymphangitis and thickening of the skin and
underlying areas, caused by obstruction of the lymphatic system by the parasite. Although,
the mortality associated with filariasis is low, the social and health consequences generated by
their chronic manifestations are important because they cause severe disability in those
subjects who suffer (blindness, deformities), which gives rise to a decrease in working capacity
and in the economy [30]. Filariasis is classified as a neglected disease by the World Health
Organization due to the limited investment by pharmaceutical companies for research into
new treatments and the low professional interest on the part of health personnel in the
countries of first world [31]. Against lymphatic filariasis, a combination of two drugs alben‐
dazole and ivermectin is used [32]
2.7. Rift Valley fever
The disease is caused by the Rift Valley fever virus, an RNA virus belonging to the Bunyavir‐
idae genus of the Phlebovirus family. The Rift Valley fever (RVF) is a peracute or acute, febrile,
mosquito-borne disease that causes fever of viral origin that affects domestic animals like cows,
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buffaloes, sheep, goats, camels, and humans [33]. The route of transmission of the disease
commonly is associated with mosquito-borne epidemics during the rainy season. RVF has been
isolated from more than 30 mosquito species, of which it is considered that the Aedes and Culex
genera are the main disease vectors [34]. The presence of RVF virus has been detected in most
countries of East, West, and Southern parts of the African continent, being the disease endemic
in Southern and Eastern Africa, but also epidemics have been reported in Egypt, Saudi Arabia,
and Yemen [35]. The high genetic diversity observed in the RVF virus in the East, West, and
Southern Africa shows the ancestral origin of the disease for these regions. Further, since
outbreaks found outside these African regions have limited genetic diversity, these outbreaks
are the result of the introduction of a single strain of the virus from the center of Africa, followed
by its spread by mosquitoes between the vulnerable animal and human population [36]. Most
cases of this disease occur in veterinarians, slaughterhouse workers, laboratory personnel, and
other employees who work directly with blood and tissues of animals. Therefore, an inacti‐
vated vaccine is available against this disease; nevertheless, it is only available to laboratory
personnel and veterinarians not being yet available to general public.
2.8. West Nile fever
West Nile fever (WNF) is transmitted to humans through the bite of Culex and Aedes mosqui‐
toes vectors of West Nile virus (WNV). This disease can affect birds, horses, and humans
causing an unapparent infection, mild febrile illness, meningitis, encephalitis, an acute
poliomyelitis-like syndrome, or death [37]. WNV is a member of the genus Flavivirus in the
Flaviviridae family. This arbovirus is maintained in nature by cycling between several bird
species and mosquitoes that support the WNV replication. The resulting symptoms of WNV
is variable, and the disease does not cause obvious signs in some species but often kills them
after suffering a fatal systemic disease in other species [38]. Among mammals, the cyclical
disease occurs mainly in horses and humans. In horses, this disease is characterized by the
presence of ataxia ranging from mild to severe, besides presenting weakness, muscle twitching,
and cranial nerve deficits [39]. The mortality rate is about one in three clinically affected horses
unvaccinated [40]. In humans, most infection cases are asymptomatic and are usually mild and
flulike if symptoms occur. The development of severe disease characterized by neurological
signs and appears to be rare in most outbreaks. However, since the 1990s, this situation
changed since the WNV became an important human and veterinary pathogen. WNV has a
broad geographic range that includes portions of Europe, Asia, Africa, Australia (Kunjin
virus), and North, Central, and South America. The incubation period of this disease ranges
from 3 to 14 days with severe symptoms, in one of every 150 people infected. Symptoms may
last from a few days to several weeks and have reported that approximately 80% of infected
people show no symptoms at all. Although all persons are able to acquire the WNV, people
older than 50 years are at higher risk of developing more severe forms of the disease. Over the
past decade, the understanding gained about the clinical spectrum of the disease as well as the
short- or long-term associated with human WNV infection has been substantially increased.
Presently, a vaccine is available only for horses, but not for humans.[41].
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2.9. Chikungunya fever
Chikungunya fever is a viral disease, manifested by fever and severe arthralgia, prevalent in
Africa, Asia, and Europe, and now emerging and little studied in the Americas and the
Caribbean Islands since 2013 [42]. Chikungunya virus is transmitted to humans by Aedes
vectors. There are two main vectors A. aegypti and A. albopictus, which are present in the tropics
and temperate zones. Although A. aegypti has always been the main vector transmitter of the
disease, in most recent outbreaks, A. albopictus has become the main vector. Chikungunya word
comes from the makonde dialect spoken by an ethnic group of southeast Tanzania and
northern Mozambique, which means the man who walks hunched over, due to the appearance
shown by patients due to the severity of joint pain that they suffer [43].
The Chikungunya virus is an enveloped positive-strand RNA virus, belonging to the Alpha‐
virus genus, group arbovirus A, of the Togaviridae family. The virus affects all humans without
distinction, being susceptible to contracting the disease individuals not previously infected
with the virus, after individuals are infected, immunity is prolonged. Chikungunya fever
epidemics spread rapidly within infected community until the development of immunity in
the population affected stops transmission. In general, about 3–28% of infected people are
asymptomatic, although they contribute to the spread of the disease. On the other hand, in the
symptomatic forms, the clinical manifestations may be acute, subacute, or chronic. After the
bite, the incubation period of the disease is 1–12 days characterized by fever, severe arthralgias,
back pain, incapacitating myalgia, and conjunctivitis. Subsequently, after 2 or 3 days, macu‐
lopapular exanthem is described (sometimes only macular) in half of the cases, distributed on
the trunk and extremities. Fever usually takes between 2 and 3 days, and leukopenia is the
rule. Since there is no specific antiviral treatment or vaccine, treatment against the disease
should be symptomatic against the symptoms presented by the patient and can be applied
antipyretics, analgesics, anti-inflammatory, and ribavirin [44].
2.10. St. Louis encephalitis
St. Louis encephalitis (SLE) is a viral disease transmitted by mosquitoes of the Culex genus,
where birds are the normal hosts of this disease that affects humans. Other potential vectors,
which can become infected and transmit the SLE to vertebrate hosts, include the mosquito
species of the Aedes, Mansonia, and Sabethes genera [45]. The SLE is a disease of greatest medical
importance in North America prior the introduction of WNV in 1999. According to studies
conducted in the United States, the sparrow has a key role in the chain of infection, and doves,
blue jay, and robin are important too, being the young of these species most important that
adults [6]. The SLEV may be enzootic in some places but eventually can occur epizootic in
which a large number of birds become infected, also being able to cause infections in humans
as isolated cases or epidemics, by the bite of mosquitoes infected with the virus. Under optimal
conditions, the extrinsic incubation period of the virus is about 10 days, staying active
throughout the life of the mosquito. Human infections with SLEV not always result in clinical
manifestations of encephalitis, which is why it often goes unnoticed, except during epidemics
[46]. The most susceptible population is of children and the elderly, and the mortality rate of
SLE is between 5% and 20%. Currently, SLE is widely distributed throughout American
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continent, from Canada, Mexico, Central and South America, and the Caribbean [6]. To date,
a vaccine against SLE has not been developed [41] because antibiotics are not effective against
this virus. Therefore, the best form of protection against the transmission of SLEV is to avoid
mosquito bites as much as possible.
2.11. Eastern equine encephalitis
Eastern equine encephalitis (EEE) is caused by the eastern equine encephalitis virus (EEEV),
an RNA virus classified in the family Togaviridae. EEE infections are characterized by
symptoms such as fever, headache, nausea and vomiting, malaise and weakness, confusion,
myalgia, arthralgia, and neck stiffness. The main vector species involved in outbreaks of
disease are Coquillettidia perturbans, Culiseta melanura, Ochlerotatus canadensis, Aedes vexans, and
Culex mosquito’s species [47]. The cycle of transmission of EEE occurs between wild birds and
mosquito vectors, and when mosquitoes bit humans they transmit the virus. Disease incuba‐
tion period varies from 4 to 10 days, and the infection can result in one of two types of disease,
systemic or encephalitis, depending on the age of the person and other host factors. The illness
lasts one to two weeks, and recovery is complete when the central nervous system is not
affected. In humans, the rate of mortality is around 3%, and many of those recovering suffer
some form of mental disability for life, and death usually occurs from 2 to 10 days after onset
of symptoms. EEEV is found throughout the Western Hemisphere and North America in areas
of the east of the Mississippi River in the US, southeastern Canada to Argentina, and Peru. The
EEE was first recognized in humans in 1938 [48]. Since then, cases have been produced
sporadically as small epidemics with a total of 223 reports between 1955 and 1993 [49],
including a peak of 36 cases in 1959 [50]. Of this case, the third part of the patients affected
died because of the disease. The diagnosis of the symptoms of EEE is difficult because the
symptoms that occur in patients are nonspecific. Currently, the only available vaccine is for
horses, and there is still no human vaccine for the general public.
2.12. Western equine encephalitis
The causal agent of Western equine encephalitis (WEE) is the WEE virus (WEEV), which is
an arbovirus of the Togaviridae family, transmitted by mosquitoes of the Culex and Culise‐
ta genres [51, 52], of which Culex tarsalis is the main vector of WEEV in western North America
[53]. The natural cycle of WEEV is maintained through alternating infection between birds
and ornithophilic mosquitoes. WEE primarily affects birds, mosquitoes, humans, and horses.
The clinical form of WEE occurs in humans and horses, which are dead-end hosts [54]. Clinical
disease  can  result  in  febrile  disease  of  variable  severity  associated  with  neurological
symptoms that range from headache to aseptic meningitis or encephalitis. The WEE has been
reported in the Western United States, Canada, Mexico, and Central and South America [54].
WEEV in humans results in mild disease in adults but can become serious encephalitis in
children and elderly people. The mortality rate is between 5% and 15%, of which about 50%
of infants who survive have permanent brain damage. People can prevent WEE infection by
avoiding outdoor activities at the primary feeding period of Culex and Culiseta mosquitoes
or using mosquito repellents. For horses, a vaccine for WEE exists in the market, but there
is no vaccine for humans [55].
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2.13. La Crosse encephalitis
La Crosse encephalitis (LAC) is a disease caused by the La Crosse encephalitis virus (LACV).
LACV is spread through the bite of infected mosquitoes of the Aedes genus, where A. triseria‐
tus is the principal vector and reservoir of LACV in nature [56]. The vertebrate of the Sciuridae
family are its normal hosts in forest habitats throughout the range of the disease [57]. Subse‐
quently, the virus can be passed to humans by feeding on infected rodents with the virus, or
transovarially from an infected female to offspring. LACV is distributed in the United States
from the upper Midwestern states, primarily Illinois, Iowa, Indiana, Minnesota, Ohio, and
Wisconsin to New York, and South to Texas, Alabama, and Georgia [58], with confirmed
human cases of LAC in 29 of the lower 48 states [59]. The disease affects the central nervous
system being able to become severe and fatal in rare cases [57]. After an incubation period of
5–15 days, LAC symptoms include fever, headache, nausea, vomiting, and fatigue and initially
presents as a nonspecific summertime illness. Severe cases involving encephalitis occur more
often in children under 16 years accompanied commonly of seizures and in some cases coma,
paralysis, and long-term disability or death. There is no specific treatment against LACV
infection, so care is based on symptoms. The best way to reduce the risk of becoming infected
with LACV is to avoid mosquito bites, use insect repellents, wear clothes to avoid bites, or
even stay indoors during peak hours of mosquito activity. Another preventive measure that
provides good results is to eliminate mosquito breeding sites. There is no antiviral drugs or
vaccine available against the LAC because antibiotics are not effective against viruses [57].
2.14. Zika fever
Zika fever (ZIKF) is caused by Zika virus (ZIKV), a flavivirus belonging to the family Flavi‐
viridae. It is a disease of monkeys and humans spread through the bite of infected Aedes
mosquito [60]. Where A. africanus and A. aegypti are the principal probable vectors [61]. Clinical
symptoms are mild headache, maculopapular eruption in different parts of the body, transient
fever, malaise, and joint pain. ZIKV is common in West and Central Africa but also occurs in
Pakistan, India, Vietnam, Thailand, the Philippines, Malaysia, Indonesia and Micronesia. In
2014, the presence of ZIKV in some American regions was reported. There is no vaccine, drugs
or specific treatment for ZIKF, so the strategies for prevention and control the disease include
insect repellents and mosquito elimination [62].
3. Mosquito control
The prevention and control of mosquito-borne diseases globally is conducted through a
comprehensive and thorough method of pest management. Where programs are not intended
to completely eliminate mosquito populations but rather are aimed to reduce their number
and therefore minimize the risk of disease transmission. Methods used to mosquito control
include the elimination of breeding sites and the control of mosquito larvae and adults.
Larvicides, by applying chemical insecticides in the breeding sites, are the best strategy to kill
larvae and pupae of mosquitoes in the water. Larvicides are present in several forms ranging
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from powder, tablets, or liquids and include methoprene, monomolecular surface films,
larvicidal oils, chemical insecticides, neurotoxic insecticides, plant-derived products, and
larvicidal bacteria [19]. Adulticides technique is usually less efficient for mosquito control.
However, it is the only way to kill adult mosquitoes and is the last line of defense in reducing
mosquito populations. Some of the adulticide used for mosquito control include products
derived from microorganisms, plants or minerals, synthetic molecules, organophosphates,
some natural pyrethrins, or synthetic pyrethroids [63].
3.1. Chemical insecticides
Since its discovery, chemical insecticides have represented the most widely method used to
control mosquito-borne vectors. However, the effects of chemical insecticides on mosquito
vector populations are usually transitory because vectors can rapidly develop resistance
against them. On the other hand, the environmental problems caused by the excessive use of
chemical insecticides are a matter of current concern because it is estimated that about 2.5
million tons of pesticides are used annually, generating worldwide damage amounting to $100
billion annually [64]. Some of the disadvantages that generates when using only chemical
products are (a) the selection of new insecticide resistance in pest populations; (b) the resur‐
gence of already treated populations; (c) the generation of waste, risks, and legal complications;
(d) the destruction of beneficial species; and (e) the high costs in equipment, labor, and material.
In addition, the highly toxic and nonbiodegradable properties of insecticides and waste
generated in soil, water, food, and crops that affect public health are additional reasons to
search new methods to help solve the problems caused by chemical insecticides [64]. Conse‐
quently, the concept of integrated control arises, a method in which pest and diseases control
is performed using chemicals, useful organisms, and cultural practices.
The progress of science and the chemical industry in the nineteenth century, with the discovery
of DDT, made possible the development and emergence of new conventional insecticides or
so-called of synthesis [65]. The most used of these insecticides of synthesis are modulators of
sodium channels (organochlorines, pyrethroids, and pyrethrins), acetylcholinesterase inhibi‐
tors (carbamates and organophosphates), and the chloride channel antagonists regulated by
the gamma-aminobutyric acid or also known as GABA (organochlorine cyclodiene and
phenylpyrazoles).
Using these conventional insecticides gave positive results against insects disease vectors at
first. However, due to its massive use, insects soon began to develop resistance to them. Thus,
an insecticide that initially was effective, just being useless in the long term. In response to this
problem, new-generation insecticides also called biorational insecticides have been developed,
whose research strategy is based on a good understanding of the physiological processes or
mechanisms specific communication of insects, and in obtaining agents that are able to affect
them. These products are divided into the following: those who are analogs of juvenile
hormone and molting, inhibitors tissue formation, pheromones, insecticides that prevent
hatching, and biological insecticides [66].
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3.1.1. Organophosphates and carbamates
Organophosphate insecticides are phosphoric acid derivatives, having activity against a wide
spectrum of invertebrate. It interferes with the action of enzymes called cholinesterases that
regulate the neurotransmitter acetylcholine, resulting in first instance to muscle cramps,
paralysis, and eventually death [67]. Therefore, these insecticides have a toxic action that blocks
an enzyme acetylcholinesterase of central and peripheral nervous system of insects, in synaptic
junctions. The enzyme rapidly hydrolyzed acetylcholine, resulting in the repolarization of the
membrane or the basal plate in neuromuscular connections, preparing for the arrival of a new
impulse. By forming strong covalent bonds between insecticide and acetylcholinesterase, the
enzyme is inhibited, causing the accumulation of acetylcholine in the synaptic junction and
the interruption of normal transmission of nerve impulses [68].
However, due to the generation of resistance in vector insects to these chemical products, the
use of many of these organophosphate and carbamates insecticides is no longer effective.
Furthermore, because cholinesterases and neurotransmitters acetylcholine also form part of
vertebrate nervous system, organophosphate pesticides are highly or moderately toxic to
vertebrates [69]. In this regard, temephos are the only organophosphate pesticide that is still
used to control mosquito larvae. Although temephos are not persistent in the environment
being that last 7–10 days [70], it has been shown in many studies the adverse effects of temephos
on a wide range of no target aquatic taxa [71]. Furthermore, carbamate pesticides, just like
organophosphates, act by inhibiting the cholinesterase enzyme. Therefore, the symptoms
experienced by insects per carbamate poisoning are similar to those experienced with orga‐
nophosphates. However, carbamate pesticides block acetylcholinesterase enzyme hydrolyz‐
ing acetylcholine in muscle by carbamylation, which is a reversible reaction [72]. Therefore,
the recovery of carbamate poisoning in humans is faster than with organophosphate intoxi‐
cation since the acetylcholinesterase enzyme is able to break apart of the carbamate [73].
3.1.2. Organochlorines, pyrethroids, and pyrethrins
Organochlorine insecticides are chlorinated hydrocarbons, which are known to be effective to
control mosquito populations. Its mode of action is by inhibiting GABA receptor in the nervous
system through the interruption of nerve impulses due to the closure of chloride channels [72].
Therefore, when an organochlorine binds to a GABA receptor, the receptor is unable to close
GABA chloride channel, which results in stimulation of the nervous system and similar
symptoms to poisoning with carbamates or organophosphates [74]. However, with the
Stockholm Convention on Persistent Organic Pollutants, which entered into force on May 17,
2004, the use of 12 chemicals including DDT, aldrin, dieldrin, heptachlor, mirex, chlordecone,
and chlordane was prohibited because of its long average life and toxicity [75]. However, an
extension clause allows countries where malaria is endemic to use DDT to control vectors that
transmit the disease. Taking into account the negative effects that DDT has for the environ‐
ment, malaria programs without the use of insecticides have been developed with the
assistance of the Pan American Health Organization [76].
On the other hand, pyrethroids and pyrethrins used to control mosquitoes break down faster
in the sunlight as opposed to chemical or microbial breakdown. However, pyrethroids are
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considered axonic poisons, composed of more stable substances, or degrade slower in the
presence of sunlight than pyrethrins and are generally effective against most of the insect pests
of agriculture. Furthermore, pyrethroids can be combined with other active ingredients, such
as piperonyl butoxide, to retard its degradation and prevents the insect’s system from
detoxifying the pyrethroid, making it more effective [72]. Delay that allows the chemical
product persists longer in the environment, requiring smaller and less frequent doses to kill
pests [77]. This type of insecticidal affects the central and peripheral nervous system of insects
and have a rapid knock-down effect, by interfering with the sodium channels of nerve
membrane causing the interruption of the transfer of ions and transmission of impulses
between nerve cells [78]. Moreover, it stimulates nerve cells to produce repetitive discharges
and eventually cause paralysis and death [79]. Furthermore, because pyrethroids act on the
nervous system of insects through a different pathway from the organophosphate pesticides,
they generally have low toxicity in mammals and birds; however, they are toxic to fish and
tadpoles [80].
3.1.3. Biorational insecticides
Biorational insecticides are those that have relatively low toxicity to humans and have few
environmental effects. Among which, methoprene is an insect growth regulator insecticide
with a broad spectrum of action that interferes with the insect life cycle preventing maturity
or reproductive stage [81]. Meanwhile, the juvenile hormone analogue is a biorational
insecticide that causes deformations in larval stage, death in the pupal stage, and sterility effect
in adults [82]. Spinosad is another biorational insecticide that comes from a Saccharopolyspora
spinosa neurotoxin, made by a mixture of spinosyns A and D. Spinosad act on the postsynaptic
nicotinic acetylcholine receptors and GABA receptors and has proven its usefulness in the
dipterans control [83]. Pyriproxyfene is another new-generation insecticide that has been
tested in adult and larval mosquitoes causing a reduction in the number of sperm, egg
production, blood feeding, and mating activity [84].
3.2. Plants and their derivates
For centuries, nature has created several active substances that, when applied correctly, can
control insect pests such as mosquito in an efficient manner. The use of plants by man with
insecticide purposes dates back to early human history. Due to their environmental advan‐
tages, the use of insecticides of vegetable origin in pest management has been increasing [85].
Among plants with potential activity against mosquitoes, Nim or Neem (Azadirachta indica)
causes stunted growth, loss of appetite, reduction of fertility, molting disorders, morphological
defects, and behavioral changes [86]. Moreover, it has been demonstrated that raw or partially
purified plant extracts are most effective for mosquito control in place of the purified com‐
pounds or extracts [87]. The snuff (Nicotiana tabacum) is used, thanks to its insecticide and insect
repellent action, where nicotine acts on the nervous system of insects through breathing,
ingestion, and contact [88]. Other plants from which oils are extracted are garlic (Ocimum
basilicum) and cinnamon (Cinnamomum osmophloeum), which have been shown to have
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insecticidal properties against larvae and adults of A. albopictus, Culex quinquefasciatus, and
Armigeres subalbatus.
3.3. Biological agents
Among biological agents used for mosquito control can be mentioned derivatives of viruses,
bacteria, and fungi. Entomopathogenic virus spreads from one insect generation to the next
causing paralysis and eventually death on mosquito larvae being more effective in the first
stage of development [89]. Within bacteria, only reports of Bacillus thuringiensis, B. sphericus,
and B. popilliae with possibilities to exercise control over dipterans insects currently exist. These
bacteria, during the sporulation process, produce protein crystals with insecticidal effect and/
or some toxins with the same effect [90]. Bacillus initially causes diarrhea and intestinal
paralysis in mosquito, giving rise to a decrease of body movements, convulsions, and general
paralysis. Internally, within the mosquito stomach, B. thuringiensis releases toxic crystals that
paralyze the insect gut stopping peristalsis, causing that the insect stop feeding and die by
starvation. Within the gut, bacteria multiply until they break the epithelium and invade the
rest of the insect body. However, its use for mosquito control is scarce and presents some
drawbacks as its duration in the environment is limited, its dispersion is rather inefficient, and
the susceptibility to bacterial infection in the pest population is very heterogeneous. There are
very sensitive individuals and other highly resistant. Fungi are other microorganisms that may
be used to control mosquito vectors, of which 400 species are known with insecticide potential.
About 20 of them have been given more attention, including those in the Lagenidium, Entomo‐
phaga, Neozygites, Entomophtora, Erynia, Aschersonia, Verticillium, Nomuraea, Hirsutella, Meta‐
rhizium, Beauveria, and Paecilomyces genera [91]. Although, entomopathogenic fungi are not as
specific as bacteria or viruses, spores persist and infect insect successive generations, so that
when the infection is established, its effects can last several years. Infection occurs by adhesion
of the spores on the insect cuticle, where these germinate and penetrate the cuticle leading to
insect colonization by mycelium. Cuticle penetration occurs through the use of an enzyme
complex that the fungi use to feed. The entomopathogenic fungus most used in controlling
mosquito infestations is Beauveria bassiana, which produces various active ingredients such as
beauvericin [92].
The biological control of mosquito larvae with predators and other biological control agents
could be a more effective and environmentally friendly strategy, thus avoiding the use of
synthetic chemicals and the consequent environmental damage [93]. Among them, some
insects and vertebrates such as fish, amphibians, and some mammals have the potential to
control mosquito disease–vector populations. Within vertebrates, amphibians, bats, and fish
have been used to control populations of mosquito. For example, using larvivorous fish
species, control of mosquito larvae in deposits used to store water has been achieved [41].
Moreover, bats are responsible for capturing flying insects such as mosquitoes at night;
similarly, toads and frogs consume large numbers of insects, slugs, worms, and other inver‐
tebrates [94]. However, the use of frogs and tadpoles for disease vector control is still largely
unexplored.
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4. Development of resistance to chemical insecticides
Insecticide resistance is defined as the development of the ability of a insect population to
tolerate doses of an insecticide, which would be lethal to the majority of individuals in a normal
population of the same species and is also the result of pressure of positive selection exerted
by the insecticide on the low frequency genes initially present in the vector insect [95].
Therefore, the development of resistance by mosquito disease vectors is of international
concern due to the increase worldwide exchange of plant matter that mosquitoes can spread
to other parts of the world, spreading resistance genes of the plagues that they have.
Most mosquito vector control programs of diseases in humans are mainly based on the use of
chemical insecticides by outdoor spraying, impregnated nets, or indoor residual spraying [96].
Thereon, the use of insecticides has helped to eradicate insect-borne diseases. In this regard,
since 1950, different classes of insecticides have been successively used. Organophosphates
and pyrethroid insecticides have been used to control mosquito populations in their larval and
adult stages. However, more recently, the disease vector control programs are based largely
on the use of synthetic pyrethroid insecticides, which are recommended by the WHO only for
impregnated nets [97]. However, the massive use of pesticides has caused detrimental effects
on the agroecosystem, such as the acquisition of resistance, pest resurgence, and environmental
pollution. Resistance has developed in more than 84 species of mosquitoes for each of the
groups of toxicological insecticides [98]. Furthermore, it was found that insecticide residues
accumulated in plants often end up in water bodies where mosquito larvae feeding on such
plant debris or grow in water bodies enriched with plant compounds and interactions between
these xenobiotics generate tolerance to insecticides or promote detoxification pathways of
these insecticides against mosquitoes [99]. In addition to abiotic factors, biotic interactions that
occur among mosquitoes, the pathogens that they transmit and their microbiome (microbes
living in the mosquito) may also occur [96]. These vary from symbionts to entomopathogen
opportunistic organisms that are able to affect various physiological host processes, such as
detoxification systems [100] or the opposite effect leading to the appearance of insecticide
resistance [101]. Furthermore, allelochemicals inducing enzyme production in insects can
increase their tolerance to pesticides [102]. On the other hand, other studies have shown that
the degree of development of a plant can affect insecticide resistance in insects [103].
There are two main mechanisms by which mosquito vectors can develop resistance to
insecticides: alterations in the target site of action and metabolic resistance, also called
increased rate of detoxification of insecticides [19]. Other less common mechanisms that
develop resistance in insects are the resistance per behavior and the resistance per decreased
penetration through the cuticle or cross resistance [104].
4.1. Resistance mechanisms
Each insecticide triggers the selection of one or more mechanisms of resistance; in addition,
an unknown number of behavioral changes in adults. For instance, changes in the target site
of action are produced when no silent mutations occur in structural genes that produce an
alteration of  amino acids responsible  for  anchoring the insecticide at  a  specific  site.  For
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example, resistance have been reported by altering the voltage-dependent sodium channel
that is the target site of action for pyrethroids and organochlorines, such as DDT, and in the
insensitive acetylcholinesterase, which is the target site of action for organophosphate and
carbamate [19]. Furthermore, the metabolic detoxification is an acquired resistance mecha‐
nism, which is regulated by the activity of certain oxidized enzymes such as mixed func‐
tion  oxidase,  esterases,  glutathione  S-transferases,  and  in  specific  cases  DDT-
dehidroclorinase. Mixed function oxidase represents an important detoxification mechanism
in the degradation of carbamates; moreover, esterases have an important role in the degrada‐
tion of phosphorus insecticides [105]. Meanwhile, the metabolic resistance occurs through
the increase in the detoxification of the insecticide. The most important form of metabolic
resistance is given by detoxifying enzymes type glutathione S-transferase, mixed function
oxidases, and esterases [78].
On the other hand, cross resistance can occur in two ways, positive and negative. The positive
cross  resistance  refers  to  resistance  to  several  insecticides  due  to  expression  in  a  single
resistance mechanism [106]. Therefore, cross resistance occurs when a single gene confers
resistance to a number of chemicals in the same group, such as kdr gene conferring resist‐
ance to DDT and pyrethroids [95]. Meanwhile, negative cross resistance occurs due to an
increase in susceptibility to the insecticide “A,” caused by the development of resistance to
insecticidal “B” and vice versa. For example, in Culex pipiens quinquefasciatus larvae, it was
found that resistance to organophosphorus insecticides increases susceptibility to pyreth‐
roid insecticides [107].
Furthermore, multiple resistances occur when two or more resistance mechanisms independ‐
ently selected are operating in the same insect [19]. However, the term multiple resistances not
necessarily involve the cross-resistance term because an insect may be resistant to two or more
insecticides, and each resistance can be attributed to different mechanisms [78]. Consequently,
each additional mechanism of resistance leads to a wide cross resistance, which restricts the
number of possible alternatives for the control and in extreme conditions, leading to highly
resistant populations to virtually all available insecticides [108].
5. Conclusion
Mosquito-borne diseases are influenced by biological, ecological, social, and economic factors.
Unfortunately, in most cases, deaths occur in rural areas where medical care is inadequate
because resources are limited. Some of the mosquito-borne disease symptoms are mild and
easy to treat; however, for other disease, antiviral drugs and antibiotics are not effective for
controlling the virus, and there is still no vaccine available for prevention. One of the strategies
used as a preventive measure to control the spread of diseases is the elimination of mosquitoes
and their breeding sites. The main strategy for the elimination of mosquitoes is the use of
chemical insecticides. However, their control is complicated because the frequent use of
chemical insecticides generates resistance and the insecticides decrease their effectiveness. The
use of plants, fungi, and bacteria with potential activity have some beneficial effects for the
environment, but its duration is limited and some mosquitoes develop high resistance. A
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promising alternative is the use of chemicals and natural insecticides intended to modify the
normal functioning of the mosquitoes that transmit diseases and which do not affect the
environment.
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